The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease

被引：4

作者：

Picardo, Sherman ^{[1
,2
]}

Seow, Cynthia H. ^{[1
,3
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

[2] Royal Perth Hosp, Dept Gastroenterol & Hepatol, Perth, WA, Australia

[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada

来源：

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY | 2020年 / 44-45卷

关键词：

Therapeutic drug monitoring; Trough drug levels; Inflammatory bowel disease; IBD; Pregnancy; Crohn's; Ulcerative colitis; IN-UTERO EXPOSURE; MONOCLONAL-ANTIBODIES; CONSENSUS STATEMENTS; CERTOLIZUMAB PEGOL; PLACENTAL-TRANSFER; ALPHA THERAPIES; ADVERSE EVENTS; BIRTH OUTCOMES; DRUG; WOMEN;

D O I：

10.1016/j.bpg.2020.101670

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Active inflammatory bowel disease during conception and pregnancy has been associated with adverse materno-fetal outcomes. Patients are often unduly concerned about the adverse effects of biologic medications on the growing fetus, however, continuing therapy is advised, with potential risks of therapy outweighed by the risks of active maternal disease. A number of physiological changes associated with pregnancy can alter the absorption, distribution and elimination of these therapies, which may impact on their safety and efficacy. We review the current evidence regarding the effects of pregnancy on the pharmacokinetics of biologic therapies, as well as drug concentration measurements during pregnancy and at time of delivery. A greater understanding of the impact of pregnancy on the pharmacokinetics of biologic therapies and the emerging utilisation of drug concentration monitoring during pregnancy may lead to improved materno-fetal outcomes in patients with inflammatory bowel disease. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页数：7

共 50 条

[41] Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
Kapoor, Akshay
Crowley, Eileen
FRONTIERS IN PEDIATRICS, 2021, 9
[42] Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
Di Sabatino, Antonio
Liberato, Lucio
Marchetti, Monia
Biancheri, Paolo
Corazza, Gino R.
INTERNAL AND EMERGENCY MEDICINE, 2011, 6 : 17 - 27
[43] RISK FACTORS FOR NON-ADHERENCE TO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
Wentworth, Brian J.
Buerlein, Ross C. D.
Nakamura, Takahiro
Tuskey, Anne G.
Overby, M. Ashely
Smolkin, Mark E.
Behm, Brian W.
GASTROENTEROLOGY, 2018, 154 (01) : S84 - S84
[44] Insights into the treatment of inflammatory bowel disease in pregnancy
Shannahan, Sarah E.
Erlich, Jonathan M.
Peppercorn, Mark A.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
[45] Emerging Natural Therapies for the Treatment of Inflammatory Bowel Disease
Joshi, Monika
Pandey, Manju
Shankar, Ravi
Ved, Akash
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2024,
[46] Biologic therapies for inflammatory eye disease
Lim, Lyndell
Suhler, Eric B.
Smith, Justine R.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 34 (04): : 365 - 374
[47] Biologic therapies and psychobiome traits in inflammatory bowel diseases
Tavakoli, P.
Vollmer-Conna, U.
Hadzi-Pavlovic, D.
Vazquez-Campos, X.
Grimm, M. C.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 117 - 117
[48] Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
Louis, Edouard
FRONTIERS IN MEDICINE, 2020, 6
[49] DOSE ESCALATION AND TREATMENT PERSISTENCE OF INFLAMMATORY BOWEL DISEASE BIOLOGIC THERAPIES IN A LARGE USA RETROSPECTIVE CLAIMS DATABASE
Wong, Gabriel
To, Tu My
Oliveri, David
Zhu, Xuelian
Park, Kun Tae
Abbass, Ibrahim M.
GASTROENTEROLOGY, 2021, 160 (06) : S347 - S348
[50] Comment on: Incidence of Adverse Psychiatric Events During the Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review
Salwen-Deremer, Jessica K.
Speed, Brittany C.
CROHNS & COLITIS 360, 2020, 2 (01)

← 1 2 3 4 5 →